You are here

News

November 15, 2017
Social Science Research with Acute HIV Cohort Seeks to Understand Volunteers' Perspectives

A new article published this week in the Journal of Medical Ethics reports on insights gleaned from in-depth interviews with members of an acute HIV infection cohort about their decision to participate in an HIV remission study with analytical treatment interruption.

The SEARCH10/RV254 cohort, which is headed by MHRP’s Dr. Jintanat Ananworanich, is an acute HIV cohort in Bangkok,...

November 6, 2017
MHRP Scientists and Collaborators at the ASTMH Annual Meeting

MHRP researchers and collaborators will give the following presentations at the 66th Annual ASTMH Meeting taking place November 5-9 in Baltimore: 

Tuesday, November 7 

Safety/Immunogenicity of a Single Intramuscular Dose of the Investigational Recombinant Chimpanzee Adenovirus Type 3-Vectored Ebola Zaire Vaccine (ChAd3-EBO-Z) in Children in Africa: A Phase 2, Randomized,...

September 15, 2017
Nigeria Biopreparedness Initiative Launches with Training Event and Site Assessment

Earlier this week, a multinational group of infectious disease physicians and laboratory experts, including those from Walter Reed Program-Nigeria (WRP-N) and the Nigerian Ministry of Defence’s Health Implementation Program (NMOD-HIP), visited the 68th Nigerian Army Reference Hospital in Yaba, Lagos, to assess the hospital’s capacity to handle highly contagious infectious diseases and conduct...

September 12, 2017
Joint West Africa Research Group Begins Infectious Disease Surveillance Study in Nigeria

The Joint West Africa Research Group (JWARG) began a study today designed to identify cases of suspected severe infectious disease at medical centers in West Africa. The study is being led by the U.S. Military HIV Research Program (MHRP) of the Walter Reed Army Institute of Research with the Nigerian Ministry of Defence.

The multi-site study opened today at the 68th Nigeria Army...

July 21, 2017
MHRP and Collaborators at the 9th IAS Conference on HIV Science

MHRP researchers and collaborators are scheduled to speak and present at the 9th IAS Conference on HIV Science taking place July 23-26 in Paris.

MHRP Researchers Speaking in Special Sessions:

Sunday, July 23

IAS HIV Cure & Cancer forum

10:30-12:00 - Panelist Dr. Jintanat Anaworanich, "Clinical Trial Design and Participation"

Monday, July 24

2:30 - 5:00 -...

July 11, 2017
Initiating ART During Acute HIV Infection Affects Trajectory of Viral Load

In a study comparing viral load in individuals during acute HIV infection, those who began antiretroviral therapy (ART) immediately had dramatically lower viral loads compared to those who did not immediately begin therapy. Findings from the study were published last week in the Journal of the International AIDS Society.

The extent of viral replication during acute HIV infection (AHI)...

July 7, 2017
Diagnosis of Acute HIV Infection and Immediate Treatment Reduces Transmission by 89% in Thai Cohort

A new study conducted by the Thai Red Cross and the U.S. Military HIV Research Program (MHRP) has shown that detecting HIV during acute infection and immediately initiating antiretroviral therapy (ART) was associated with an estimated 89% reduction in HIV transmission in a Thai cohort compared to those who receive no intervention during acute infection. Findings from the study were published...

July 6, 2017
Characterization of T Cells Infected with Simian Immunodeficiency Virus Reveals Host-pathogen Interactions

HIV and its simian counterpart, SIV, infect and kill CD4 T cells in the immune system, resulting in a massive depletion that ultimately leads to AIDS in the absence of antiretroviral therapy (ART). With effective therapy, CD4 T cells are largely preserved, but some harbor latent virus that can persist for decades and reemerge when ART is interrupted, presenting a hurdle to curing HIV.

...

June 20, 2017
Late HIV Vaccine Boost Elicits Higher Immune Response in Volunteers from the RV144 Thai Trial

The Army-led RV144 HIV vaccine trial provided the first evidence in humans that a safe and effective preventive HIV vaccine is possible. A new study has shown that boosting RV144 volunteers 6-8 years later with AIDSVAX B/E vaccine resulted in higher immune responses than were seen immediately after RV144.

In the RV144 vaccine trial, led by the U.S. Military HIV Research Program at the...

May 3, 2017
Dual-use Heroin Vaccine Elicits Immune Response in Mice

A novel combination vaccine designed to treat heroin addiction and target HIV was found to elicit immune responses in mice and dull their response to injected heroin in a recent preclinical trial. Findings from the study were published today in the online journal npj Vaccines.

A team of U.S. government researchers led by scientists from the Walter Reed Institute of Research (WRAIR)...

Pages